247 related articles for article (PubMed ID: 33671651)
21. Enhanced expression of Fas Ligand (FasL) in the lower airways of patients with fibrotic interstitial lung diseases (ILDs).
Kopiński P; Balicka-Ślusarczyk B; Dyczek A; Szpechciński A; Przybylski G; Jarzemska A; Wandtke T; Jankowski M; Iwaniec T; Chorostowska-Wynimko J
Folia Histochem Cytobiol; 2011; 49(4):636-45. PubMed ID: 22252758
[TBL] [Abstract][Full Text] [Related]
22. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
[TBL] [Abstract][Full Text] [Related]
24. Diacylglycerol kinase alpha regulates the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes.
Alonso R; Rodríguez MC; Pindado J; Merino E; Mérida I; Izquierdo M
J Biol Chem; 2005 Aug; 280(31):28439-50. PubMed ID: 15870081
[TBL] [Abstract][Full Text] [Related]
25. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
Kozlowski M; Kowalczuk O; Sulewska A; Dziegielewski P; Lapuc G; Laudanski W; Niklinska W; Chyczewski L; Niklinski J; Laudanski J
Folia Histochem Cytobiol; 2007; 45(3):199-204. PubMed ID: 17951168
[TBL] [Abstract][Full Text] [Related]
26. Considering Fas ligand as a target for therapy.
Linkermann A; Qian J; Lettau M; Kabelitz D; Janssen O
Expert Opin Ther Targets; 2005 Feb; 9(1):119-34. PubMed ID: 15757486
[TBL] [Abstract][Full Text] [Related]
27. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
28. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis.
Kuwano K; Hagimoto N; Kawasaki M; Nakamura N; Shirakawa K; Maeyama T; Hara N
Int Arch Allergy Immunol; 2000 Jul; 122(3):209-15. PubMed ID: 10899765
[TBL] [Abstract][Full Text] [Related]
29. IL-13 and TH2 cytokine exposure triggers matrix metalloproteinase 7-mediated Fas ligand cleavage from bronchial epithelial cells.
Wadsworth SJ; Atsuta R; McIntyre JO; Hackett TL; Singhera GK; Dorscheid DR
J Allergy Clin Immunol; 2010 Aug; 126(2):366-74, 374.e1-8. PubMed ID: 20624652
[TBL] [Abstract][Full Text] [Related]
30. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
31. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
32. Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1.
Sakamoto N; Mukae H; Fujii T; Kakugawa T; Kaida H; Kadota J; Kohno S
Respir Med; 2004 Mar; 98(3):213-9. PubMed ID: 15002756
[TBL] [Abstract][Full Text] [Related]
33. Understanding the Effects of Age and T-Cell Differentiation on COVID-19 Severity: Implicating a Fas/FasL-mediated Feed-Forward Controller of T-Cell Differentiation.
Leonardi AJ; Argyropoulos CP; Hamdy A; Proenca RB
Front Immunol; 2022; 13():853606. PubMed ID: 35309371
[No Abstract] [Full Text] [Related]
34. Involvement of soluble Fas Ligand in germ cell apoptosis in testis of rats undergoing autoimmune orchitis.
Jacobo PV; Fass M; Pérez CV; Jarazo-Dietrich S; Lustig L; Theas MS
Cytokine; 2012 Nov; 60(2):385-92. PubMed ID: 22892327
[TBL] [Abstract][Full Text] [Related]
35. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
36. High concentrations of soluble Fas ligand in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Shikuwa C; Kadota J; Mukae H; Iwashita T; Kaida H; Ishii H; Ishimatsu Y; Kohno S
Respiration; 2002; 69(3):242-6. PubMed ID: 12097768
[TBL] [Abstract][Full Text] [Related]
37. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis.
Hashimoto H; Tanaka M; Suda T; Tomita T; Hayashida K; Takeuchi E; Kaneko M; Takano H; Nagata S; Ochi T
Arthritis Rheum; 1998 Apr; 41(4):657-62. PubMed ID: 9550474
[TBL] [Abstract][Full Text] [Related]
38. Storage, expression and function of Fas ligand, the key death factor of immune cells.
Lettau M; Paulsen M; Kabelitz D; Janssen O
Curr Med Chem; 2008; 15(17):1684-96. PubMed ID: 18673218
[TBL] [Abstract][Full Text] [Related]
39. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.
Cippitelli M; Fionda C; Di Bona D; Di Rosa F; Lupo A; Piccoli M; Frati L; Santoni A
J Immunol; 2002 Feb; 168(3):1154-66. PubMed ID: 11801650
[TBL] [Abstract][Full Text] [Related]
40. Fas/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungs.
Bień K; Sokołowska J; Bąska P; Nowak Z; Stankiewicz W; Krzyzowska M
Mediators Inflamm; 2015; 2015():281613. PubMed ID: 25873756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
